| Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 17698902 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Because GH exerted beneficial effects in various experimental models of heart failure, we investigated the effects of GH on physical exercise capacity and cardiopulmonary performance in patients with dilated cardiomyopathy and chronic heart failure (CHF). METHODS: Twenty-two patients with CHF (New York Heart Association functional class II-III) underwent spirometry and a symptom-limited, cardiopulmonary exercise testing before and after 3 months of GH (n = 11; seven males; seven idiopathic; 57 +/- 11 yr; 4 IU sc every other day) or placebo (n = 11; eight males; six idiopathic; 54 +/- 10 yr) administration, in a randomized, double-blind trial. Background CHF therapy remained unchanged. RESULTS: GH, but not placebo, increased IGF-I serum concentration (from 144 +/- 35 to 293 +/- 58 ng/ml; P < 0.005) and improved New York Heart Association functional class (from 2.4 +/- 0.5 to 1.8 +/- 0.4; P < 0.005), exercise duration (from 831 +/- 273 to 925 +/- 266 sec; P < 0.005), peak power output (from 245 +/- 127 to 280 +/- 132 W; P < 0.05), peak minute ventilation (from 52.5 +/- 16.1 to 61.3 +/- 17.3 liters/min; P < 0.05), peak oxygen consumption (from 19.8 +/- 5.6 to 25.1 +/- 5.6 ml/kg.min; P < 0.005), and anaerobic threshold (from 14.9 +/- 4.8 to 20.0 +/- 4.5 ml/kg.min; P < 0.005) without affecting lung function parameters. Furthermore, the slope of the relationship between minute ventilation and pulmonary carbon dioxide production (ventilatory efficiency) decreased from 34.7 +/- 5.1 to 31.7 +/- 5.3 (P < 0.005), whereas the slope of the relation between percent predicted heart rate reserve used and percent observed metabolic reserve used (chronotropic index) rose from 0.57 +/- 0.20 to 0.69 +/- 0.18 (P < 0.005). CONCLUSION: Given the predictive value of physical exercise capacity and cardiopulmonary performance in CHF progression, these data provide additional insights into the mechanisms by which GH may potentially benefit CHF patients. |
| | |
Authors:
|
Serafino Fazio; Emiliano A Palmieri; Flora Affuso; Antonio Cittadini; Graziella Castellano; Teresa Russo; Antonio Ruvolo; Raffaele Napoli; Luigi Saccà |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2007-08-14 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 92 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-11-08 Completed Date: 2008-01-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 4218-23 Citation Subset: AIM; IM |
Affiliation:
|
Department of Internal Medicine, Cardiovascular and Immunological Sciences, University Federico II School of Medicine, 80131 Naples, Italy. fazio@unina.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anaerobic Threshold
/
drug effects Cardiomyopathy, Dilated / drug therapy, physiopathology Cardiovascular System / drug effects* Chronic Disease Double-Blind Method Echocardiography Exercise Tolerance / drug effects* Female Growth Hormone / therapeutic use* Heart Failure / drug therapy*, physiopathology*, ultrasonography Heart Function Tests / drug effects Humans Lung / drug effects* Male Middle Aged Oxygen Consumption / physiology Respiratory Function Tests Vital Capacity |
| Chemical | |
Reg. No./Substance:
|
9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence of symptomatic androgen deficiency in men.
Next Document: Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with ma...